Skip to main content

Adrenal Tumors

  • Living reference work entry
  • First Online:
Urologic Oncology

Abstract

The adrenals are two retroperitoneal organs with multiple endocrine and neurocrine functions. The most common problems are related to the function and dysfunction of them. However, they are organs that are not except of neoplasia development or metastases from other organs.

In this chapter, the diagnosis and management of the main malignant adrenal problems would be developed, which include adrenal carcinoma, malignant pheochromocytoma, and metastases to the adrenals.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Institutional subscriptions

References

  • Abiven G, Coste J, Groussin L, Anract P, Tissier F, Legmann P, et al. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab. 2006;91(7): 2650–5.

    Article  CAS  PubMed  Google Scholar 

  • Adjalle R, Plouin PF, Pacak K, Lehnert H. Treatment of malignant pheochromocytoma. Horm Metab Res. 2009;41(9):687–96.

    Article  CAS  PubMed  Google Scholar 

  • Allolio B, Fassnacht M. Clinical review: adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab. 2006;91(6):2027–37.

    Article  CAS  PubMed  Google Scholar 

  • Arlt W, Biehl M, Taylor AE, Hahner S, Libe R, Hughes BA, et al. Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. J Clin Endocrinol Metab. 2011;96(12): 3775–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Assie G, Antoni G, Tissier F, Caillou B, Abiven G, Gicquel C, et al. Prognostic parameters of metastatic adrenocortical carcinoma. J Clin Endocrinol Metab. 2007;92(1):148–54.

    Article  CAS  PubMed  Google Scholar 

  • Ayala-Ramirez M, Chougnet CN, Habra MA, Palmer JL, Leboulleux S, Cabanillas ME, et al. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. J Clin Endocrinol Metab. 2012;97(11):4040–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Baguet JP, Hammer L, Mazzuco TL, Chabre O, Mallion JM, Sturm N, et al. Circumstances of discovery of phaeochromocytoma: a retrospective study of 41 consecutive patients. Eur J Endocrinol. 2004;150(5):681–6.

    Article  CAS  PubMed  Google Scholar 

  • Ball MW, Hemal AK, Allaf ME. International Consultation on Urological Diseases and European Association of Urology International Consultation on minimally invasive surgery in urology: laparoscopic and robotic adrenalectomy. BJU Int. 2016;119:13.

    Article  PubMed  Google Scholar 

  • Beard CM, Sheps SG, Kurland LT, Carney JA, Lie JT. Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc. 1983;58(12):802–4.

    CAS  PubMed  Google Scholar 

  • Bharwani N, Rockall AG, Sahdev A, Gueorguiev M, Drake W, Grossman AB, et al. Adrenocortical carcinoma: the range of appearances on CT and MRI. AJR Am J Roentgenol. 2011;196(6):W706–14.

    Article  PubMed  Google Scholar 

  • Blaker H, Sutter C, Kadmon M, Otto HF, Von Knebel-Doeberitz M, Gebert J, et al. Analysis of somatic APC mutations in rare extracolonic tumors of patients with familial adenomatous polyposis coli. Genes Chromosomes Cancer. 2004;41(2):93–8.

    Article  PubMed  CAS  Google Scholar 

  • Boland GW, Lee MJ, Gazelle GS, Halpern EF, McNicholas MM, Mueller PR. Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. AJR Am J Roentgenol. 1998;171(1):201–4.

    Article  CAS  PubMed  Google Scholar 

  • Bonnet S, Gaujoux S, Launay P, Baudry C, Chokri I, Ragazzon B, et al. Wnt/beta-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and -nonsecreting tumors. J Clin Endocrinol Metab. 2011;96(2):E419–26.

    Article  CAS  PubMed  Google Scholar 

  • Bourcigaux N, Gaston V, Logie A, Bertagna X, Le Bouc Y, Gicquel C. High expression of cyclin E and G1 CDK and loss of function of p57KIP2 are involved in proliferation of malignant sporadic adrenocortical tumors. J Clin Endocrinol Metab. 2000;85(1):322–30.

    CAS  PubMed  Google Scholar 

  • Bravo EL. Pheochromocytoma: new concepts and future trends. Kidney Int. 1991;40(3):544–56.

    Article  CAS  PubMed  Google Scholar 

  • Brix D, Allolio B, Fenske W, Agha A, Dralle H, Jurowich C, et al. Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. Eur Urol. 2010;58(4): 609–15.

    Article  PubMed  Google Scholar 

  • Butler C, Butler WM, Rizvi AA. Sustained remission with the kinase inhibitor sorafenib in stage IV metastatic adrenocortical carcinoma. Endocr Pract. 2010;16(3): 441–5.

    Article  PubMed  Google Scholar 

  • Caoili EM, Korobkin M, Brown RK, Mackie G, Shulkin BL. Differentiating adrenal adenomas from nonadenomas using (18)F-FDG PET/CT: quantitative and qualitative evaluation. Acad Radiol. 2007;14(4): 468–75.

    Article  PubMed  Google Scholar 

  • Cawood TJ, Hunt PJ, O'Shea D, Cole D, Soule S. Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? Eur J Endocrinol. 2009;161(4):513–27.

    Article  CAS  PubMed  Google Scholar 

  • Chen H, Sippel RS, O'Dorisio MS, Vinik AI, Lloyd RV, Pacak K, et al. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. 2010;39(6):775–83.

    Article  PubMed  PubMed Central  Google Scholar 

  • Clarke MR, Weyant RJ, Watson CG, Carty SE. Prognostic markers in pheochromocytoma. Hum Pathol. 1998;29(5):522–6.

    Article  CAS  PubMed  Google Scholar 

  • Crucitti F, Bellantone R, Ferrante A, Boscherini M, Crucitti P. The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. Surgery. 1996;119(2):161–70.

    Article  CAS  PubMed  Google Scholar 

  • Dackiw AP, Lee JE, Gagel RF, Evans DB. Adrenal cortical carcinoma. World J Surg. 2001;25(7):914–26.

    Article  CAS  PubMed  Google Scholar 

  • Datrice NM, Langan RC, Ripley RT, Kemp CD, Steinberg SM, Wood BJ, et al. Operative management for recurrent and metastatic adrenocortical carcinoma. J Surg Oncol. 2012;105(7):709–13.

    Article  PubMed  Google Scholar 

  • DeChiara TM, Robertson EJ, Efstratiadis A. Parental imprinting of the mouse insulin-like growth factor II gene. Cell. 1991;64(4):849–59.

    Article  CAS  PubMed  Google Scholar 

  • Ellis RJ, Patel D, Prodanov T, Sadowski S, Nilubol N, Adams K, et al. Response after surgical resection of metastatic pheochromocytoma and paraganglioma: can postoperative biochemical remission be predicted? J Am Coll Surg. 2013;217(3):489–96.

    Article  PubMed  PubMed Central  Google Scholar 

  • Else T, Williams AR, Sabolch A, Jolly S, Miller BS, Hammer GD. Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2014;99(2):455–61.

    Article  CAS  PubMed  Google Scholar 

  • Fassnacht M, Allolio B. Clinical management of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab. 2009;23(2):273–89.

    Article  CAS  PubMed  Google Scholar 

  • Fassnacht M, Hahner S, Polat B, Koschker AC, Kenn W, Flentje M, et al. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab. 2006;91(11): 4501–4.

    Article  CAS  PubMed  Google Scholar 

  • Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer. 2009;115(2):243–50.

    Article  PubMed  Google Scholar 

  • Fassnacht M, Johanssen S, Fenske W, Weismann D, Agha A, Beuschlein F, et al. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. J Clin Endocrinol Metab. 2010;95(11):4925–32.

    Article  CAS  PubMed  Google Scholar 

  • Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366(23):2189–97.

    Article  CAS  PubMed  Google Scholar 

  • Frilling A, Tecklenborg K, Weber F, Kuhl H, Muller S, Stamatis G, et al. Importance of adrenal incidentaloma in patients with a history of malignancy. Surgery. 2004;136(6):1289–96.

    Article  PubMed  Google Scholar 

  • Gedik GK, Hoefnagel CA, Bais E. Olmos RA. 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2008;35(4):725–33.

    Article  CAS  PubMed  Google Scholar 

  • Gicquel C, Raffin-Sanson ML, Gaston V, Bertagna X, Plouin PF, Schlumberger M, et al. Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. J Clin Endocrinol Metab. 1997;82(8):2559–65.

    CAS  PubMed  Google Scholar 

  • Gicquel C, Bertagna X, Gaston V, Coste J, Louvel A, Baudin E, et al. Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res. 2001;61(18): 6762–7.

    CAS  PubMed  Google Scholar 

  • Goffredo P, Sosa JA, Roman SA. Malignant pheochromocytoma and paraganglioma: a population level analysis of long-term survival over two decades. J Surg Oncol. 2013;107(6):659–64.

    Article  PubMed  Google Scholar 

  • Goffredo P, Adam MA, Thomas SM, Scheri RP, Sosa JA, Roman SA. Patterns of use and short-term outcomes of minimally invasive surgery for malignant pheochromocytoma: a population-level study. World J Surg. 2015;39(8):1966–73.

    Article  CAS  PubMed  Google Scholar 

  • Goldstein RE, O’Neill JA Jr, Holcomb GW 3rd, Morgan WM 3rd, Neblett WW 3rd, Oates JA, et al. Clinical experience over 48 years with pheochromocytoma. Ann Surg. 1999;229(6):755–64; discussion 64-6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Groussin L, Bonardel G, Silvera S, Tissier F, Coste J, Abiven G, et al. 18F-Fluorodeoxyglucose positron emission tomography for the diagnosis of adrenocortical tumors: a prospective study in 77 operated patients. J Clin Endocrinol Metab. 2009;94(5):1713–22.

    Article  CAS  PubMed  Google Scholar 

  • Guerrero MA, Schreinemakers JM, Vriens MR, Suh I, Hwang J, Shen WT, et al. Clinical spectrum of pheochromocytoma. J Am Coll Surg. 2009;209(6):727–32.

    Article  PubMed  Google Scholar 

  • Guller U, Turek J, Eubanks S, Delong ER, Oertli D, Feldman JM. Detecting pheochromocytoma: defining the most sensitive test. Ann Surg. 2006;243(1):102–7.

    Article  PubMed  PubMed Central  Google Scholar 

  • Hadoux J, Favier J, Scoazec JY, Leboulleux S, Al Ghuzlan A, Caramella C, et al. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Int J Cancer. 2014;135(11):2711–20.

    Article  CAS  PubMed  Google Scholar 

  • Hisada M, Garber JE, Fung CY, Fraumeni JF Jr, Li FP. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst. 1998;90(8):606–11.

    Article  CAS  PubMed  Google Scholar 

  • Icard P, Goudet P, Charpenay C, Andreassian B, Carnaille B, Chapuis Y, et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg. 2001;25(7):891–7.

    Article  CAS  PubMed  Google Scholar 

  • Ilias I, Sahdev A, Reznek RH, Grossman AB, Pacak K. The optimal imaging of adrenal tumours: a comparison of different methods. Endocr Relat Cancer. 2007;14(3):587–99.

    Article  PubMed  Google Scholar 

  • Ilvesmaki V, Kahri AI, Miettinen PJ, Voutilainen R. Insulin-like growth factors (IGFs) and their receptors in adrenal tumors: high IGF-II expression in functional adrenocortical carcinomas. J Clin Endocrinol Metab. 1993;77(3):852–8.

    CAS  PubMed  Google Scholar 

  • Jhala NC, Jhala D, Eloubeidi MA, Chhieng DC, Crowe DR, Roberson J, et al. Endoscopic ultrasound-guided fine-needle aspiration biopsy of the adrenal glands: analysis of 24 patients. Cancer. 2004;102(5): 308–14.

    Article  PubMed  Google Scholar 

  • Johanssen S, Hahner S, Saeger W, Quinkler M, Beuschlein F, Dralle H, et al. Deficits in the management of patients with adrenocortical carcinoma in Germany. Dtsch Arztebl Int. 2010;107(50):885–91.

    PubMed  PubMed Central  Google Scholar 

  • Khorram-Manesh A, Ahlman H, Jansson S, Wangberg B, Nilsson O, Jakobsson CE, et al. Adrenocortical carcinoma: surgery and mitotane for treatment and steroid profiles for follow-up. World J Surg. 1998;22(6): 605–11; discussion 11-2

    Article  CAS  PubMed  Google Scholar 

  • Kikuchi A. Tumor formation by genetic mutations in the components of the Wnt signaling pathway. Cancer Sci. 2003;94(3):225–9.

    Article  CAS  PubMed  Google Scholar 

  • Kim AC, Reuter AL, Zubair M, Else T, Serecky K, Bingham NC, et al. Targeted disruption of beta-catenin in Sf1-expressing cells impairs development and maintenance of the adrenal cortex. Development. 2008;135(15):2593–602.

    Article  CAS  PubMed  Google Scholar 

  • Koschker AC, Fassnacht M, Hahner S, Weismann D, Allolio B. Adrenocortical carcinoma – improving patient care by establishing new structures. Exp Clin Endocrinol Diabetes. 2006;114(2):45–51.

    Article  CAS  PubMed  Google Scholar 

  • Kuruba R, Gallagher SF. Current management of adrenal tumors. Curr Opin Oncol. 2008;20(1):34–46.

    Article  PubMed  Google Scholar 

  • Lacroix A. Approach to the patient with adrenocortical carcinoma. J Clin Endocrinol Metab. 2010;95(11): 4812–22.

    Article  CAS  PubMed  Google Scholar 

  • Latronico AC, Chrousos GP. Neoplasms of the adrenal cortex. Clinical and basic aspects. Cancer Treat Res. 1997;89:217–37.

    Article  CAS  PubMed  Google Scholar 

  • Latronico AC, Pinto EM, Domenice S, Fragoso MC, Martin RM, Zerbini MC, et al. An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. J Clin Endocrinol Metab. 2001;86(10):4970–3.

    Article  CAS  PubMed  Google Scholar 

  • Leboulleux S, Dromain C, Bonniaud G, Auperin A, Caillou B, Lumbroso J, et al. Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. J Clin Endocrinol Metab. 2006;91(3):920–5.

    Article  CAS  PubMed  Google Scholar 

  • Lee JE, Evans DB, Hickey RC, Sherman SI, Gagel RF, Abbruzzese MC, et al. Unknown primary cancer presenting as an adrenal mass: frequency and implications for diagnostic evaluation of adrenal incidentalomas. Surgery. 1998;124(6):1115–22.

    Article  CAS  PubMed  Google Scholar 

  • Lee JO, Lee KW, Kim CJ, Kim YJ, Lee HE, Kim H, et al. Metastatic adrenocortical carcinoma treated with sunitinib: a case report. Jpn J Clin Oncol. 2009;39(3): 183–5.

    Article  PubMed  Google Scholar 

  • Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA. 2002;287(11):1427–34.

    Article  CAS  PubMed  Google Scholar 

  • Lenert JT, Barnett CC Jr, Kudelka AP, Sellin RV, Gagel RF, Prieto VG, et al. Evaluation and surgical resection of adrenal masses in patients with a history of extra-adrenal malignancy. Surgery. 2001;130(6):1060–7.

    Article  CAS  PubMed  Google Scholar 

  • Libe R, Groussin L, Tissier F, Elie C, Rene-Corail F, Fratticci A, et al. Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity. Clin Cancer Res. 2007;13(3):844–50.

    Article  CAS  PubMed  Google Scholar 

  • Lubitz JA, Freeman L, Okun R. Mitotane use in inoperable adrenal cortical carcinoma. JAMA. 1973;223(10): 1109–12.

    Article  CAS  PubMed  Google Scholar 

  • Lughezzani G, Sun M, Perrotte P, Jeldres C, Alasker A, Isbarn H, et al. The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. Eur J Cancer. 2010;46(4):713–9.

    Article  PubMed  Google Scholar 

  • Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med. 1990;322(17): 1195–201.

    Article  CAS  PubMed  Google Scholar 

  • Lutz A, Stojkovic M, Schmidt M, Arlt W, Allolio B, Reincke M. Adrenocortical function in patients with macrometastases of the adrenal gland. Eur J Endocrinol. 2000;143(1):91–7.

    Article  CAS  PubMed  Google Scholar 

  • Mackie GC, Shulkin BL, Ribeiro RC, Worden FP, Gauger PG, Mody RJ, et al. Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. J Clin Endocrinol Metab. 2006;91(7):2665–71.

    Article  CAS  PubMed  Google Scholar 

  • Mantero F, Terzolo M, Arnaldi G, Osella G, Masini AM, Ali A, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab. 2000;85(2):637–44.

    CAS  PubMed  Google Scholar 

  • Metser U, Miller E, Lerman H, Lievshitz G, Avital S, Even-Sapir E. 18F-FDG PET/CT in the evaluation of adrenal masses. J Nucl Med. 2006;47(1):32–7.

    PubMed  Google Scholar 

  • Morimoto R, Satoh F, Murakami O, Suzuki T, Abe T, Tanemoto M, et al. Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas. Endocr J. 2008;55(1):49–55.

    Article  PubMed  Google Scholar 

  • Ng L, Libertino JM. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Urol. 2003;169(1):5–11.

    Article  PubMed  Google Scholar 

  • Niemeijer ND, Alblas G, van Hulsteijn LT, Dekkers OM, Corssmit EP. Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis. Clin Endocrinol. 2014;81(5): 642–51.

    Article  CAS  Google Scholar 

  • Ohgaki H, Kleihues P, Heitz PU. p53 mutations in sporadic adrenocortical tumors. Int J Cancer. 1993;54(3): 408–10.

    Article  CAS  PubMed  Google Scholar 

  • Park BK, Kim CK, Kim B, Lee JH. Comparison of delayed enhanced CT and chemical shift MR for evaluating hyperattenuating incidental adrenal masses. Radiology. 2007;243(3):760–5.

    Article  PubMed  Google Scholar 

  • Paton BL, Novitsky YW, Zerey M, Harrell AG, Norton HJ, Asbun H, et al. Outcomes of adrenal cortical carcinoma in the United States. Surgery. 2006;140(6):914–20; discussion 9-20

    Article  PubMed  Google Scholar 

  • Polat B, Fassnacht M, Pfreundner L, Guckenberger M, Bratengeier K, Johanssen S, et al. Radiotherapy in adrenocortical carcinoma. Cancer. 2009;115(13): 2816–23.

    Article  PubMed  Google Scholar 

  • Porpiglia F, Fiori C, Daffara F, Zaggia B, Bollito E, Volante M, et al. Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer. Eur Urol. 2010;57(5):873–8.

    Article  PubMed  Google Scholar 

  • Quinkler M, Hahner S, Wortmann S, Johanssen S, Adam P, Ritter C, et al. Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. J Clin Endocrinol Metab. 2008;93(6):2057–62.

    Article  CAS  PubMed  Google Scholar 

  • Reibetanz J, Jurowich C, Erdogan I, Nies C, Rayes N, Dralle H, et al. Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma. Ann Surg. 2012;255(2):363–9.

    Article  PubMed  Google Scholar 

  • Reincke M, Karl M, Travis WH, Mastorakos G, Allolio B, Linehan HM, et al. p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. J Clin Endocrinol Metab. 1994;78(3):790–4.

    CAS  PubMed  Google Scholar 

  • Roman S. Adrenocortical carcinoma. Curr Opin Oncol. 2006;18(1):36–42.

    Article  PubMed  Google Scholar 

  • Sabolch A, Else T, Griffith KA, Ben-Josef E, Williams A, Miller BS, et al. Adjuvant radiation therapy improves local control after surgical resection in patients with localized adrenocortical carcinoma. Int J Radiat Oncol Biol Phys. 2015;92(2):252–9.

    Article  PubMed  Google Scholar 

  • Sawka AM, Jaeschke R, Singh RJ, Young WF Jr. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab. 2003;88(2):553–8.

    Article  CAS  PubMed  Google Scholar 

  • Schteingart DE, Doherty GM, Gauger PG, Giordano TJ, Hammer GD, Korobkin M, et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer. 2005;12(3):667–80.

    Article  CAS  PubMed  Google Scholar 

  • Schulick RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol. 1999;6(8):719–26.

    Article  CAS  PubMed  Google Scholar 

  • Sgourakis G, Lanitis S, Kouloura A, Zaphiriadou P, Karkoulias K, Raptis D, et al. Laparoscopic versus open adrenalectomy for stage I/II adrenocortical carcinoma: meta-analysis of outcomes. J Investig Surg. 2015;28(3):145–52.

    Article  Google Scholar 

  • Smith TG, Clark SK, Katz DE, Reznek RH, Phillips RK. Adrenal masses are associated with familial adenomatous polyposis. Dis Colon Rectum. 2000;43(12): 1739–42.

    Article  CAS  PubMed  Google Scholar 

  • Stein PP, Black HR. A simplified diagnostic approach to pheochromocytoma. A review of the literature and report of one institution’s experience. Medicine. 1991;70(1):46–66.

    Article  CAS  PubMed  Google Scholar 

  • Stojadinovic A, Ghossein RA, Hoos A, Nissan A, Marshall D, Dudas M, et al. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol. 2002;20(4):941–50.

    Article  CAS  PubMed  Google Scholar 

  • Sullivan M, Boileau M, Hodges CV. Adrenal cortical carcinoma. J Urol. 1978;120(6):660–5.

    Article  CAS  PubMed  Google Scholar 

  • Sze WC, Grossman AB, Goddard I, Amendra D, Shieh SC, Plowman PN, et al. Sequelae and survivorship in patients treated with (131)I-MIBG therapy. Br J Cancer. 2013;109(3):565–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tadjine M, Lampron A, Ouadi L, Bourdeau I. Frequent mutations of beta-catenin gene in sporadic secreting adrenocortical adenomas. Clin Endocrinol. 2008;68(2):264–70.

    CAS  Google Scholar 

  • Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007;356(23):2372–80.

    Article  CAS  PubMed  Google Scholar 

  • Timmers HJ, Kozupa A, Chen CC, Carrasquillo JA, Ling A, Eisenhofer G, et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol. 2007;25(16):2262–9.

    Article  PubMed  Google Scholar 

  • Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Eisenhofer G, et al. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. J Natl Cancer Inst. 2012;104(9):700–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tissier F, Cavard C, Groussin L, Perlemoine K, Fumey G, Hagnere AM, et al. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res. 2005;65(17): 7622–7.

    Article  CAS  PubMed  Google Scholar 

  • van der Harst E, de Herder WW, Bruining HA, Bonjer HJ, de Krijger RR, Lamberts SW, et al. [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas. J Clin Endocrinol Metab. 2001;86(2):685–93.

    PubMed  Google Scholar 

  • van Hulsteijn LT, Niemeijer ND, Dekkers OM, Corssmit EP. (131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis. Clin Endocrinol. 2014;80(4):487–501.

    Article  CAS  Google Scholar 

  • Varley JM, McGown G, Thorncroft M, James LA, Margison GP, Forster G, et al. Are there low-penetrance TP53 Alleles? evidence from childhood adrenocortical tumors. Am J Hum Genet. 1999;65(4):995–1006.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Vassilopoulou-Sellin R, Schultz PN. Adrenocortical carcinoma. Clinical outcome at the end of the 20th century. Cancer. 2001;92(5):1113–21.

    Article  CAS  PubMed  Google Scholar 

  • Vogel J, Atanacio AS, Prodanov T, Turkbey BI, Adams K, Martucci V, et al. External beam radiation therapy in treatment of malignant pheochromocytoma and paraganglioma. Front Oncol. 2014;4:166.

    Article  PubMed  PubMed Central  Google Scholar 

  • Volante M, Bollito E, Sperone P, Tavaglione V, Daffara F, Porpiglia F, et al. Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification. Histopathology. 2009;55(5):535–43.

    Article  PubMed  Google Scholar 

  • Wajchenberg BL, Albergaria Pereira MA, Medonca BB, Latronico AC, Campos Carneiro P, Alves VA, et al. Adrenocortical carcinoma: clinical and laboratory observations. Cancer. 2000;88(4):711–36.

    Article  CAS  PubMed  Google Scholar 

  • Whalen RK, Althausen AF, Daniels GH. Extra-adrenal pheochromocytoma. J Urol. 1992;147(1):1–10.

    Article  CAS  PubMed  Google Scholar 

  • Xiao XR, Ye LY, Shi LX, Cheng GF, Li YT, Zhou BM. Diagnosis and treatment of adrenal tumours: a review of 35 years' experience. Br J Urol. 1998;82(2): 199–205.

    Article  CAS  PubMed  Google Scholar 

  • Zeiger MA, Thompson GB, Duh QY, Hamrahian AH, Angelos P, Elaraj D, et al. American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons Medical Guidelines for the Management of Adrenal Incidentalomas: executive summary of recommendations. Endocr Pract. 2009;15(5):450–3.

    Article  PubMed  Google Scholar 

  • Zhao J, Speel EJ, Muletta-Feurer S, Rutimann K, Saremaslani P, Roth J, et al. Analysis of genomic alterations in sporadic adrenocortical lesions. Gain of chromosome 17 is an early event in adrenocortical tumorigenesis. Am J Pathol. 1999;155(4):1039–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zini L, Porpiglia F, Fassnacht M. Contemporary management of adrenocortical carcinoma. Eur Urol. 2011;60(5):1055–65.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Luciano A. Nuñez Bragayrac .

Editor information

Editors and Affiliations

Section Editor information

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Nuñez Bragayrac, L.A., Schwaab, T. (2019). Adrenal Tumors. In: Merseburger, A., Burger, M. (eds) Urologic Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-42603-7_41-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-42603-7_41-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-42603-7

  • Online ISBN: 978-3-319-42603-7

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics